QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.105.020479v1 69/5/1615    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olivier, S. Articles by Franchimont, N. Search for Related Content PubMed PubMed Citation Articles by Olivier, S. Articles by Franchimont, N.

Raloxifene-Induced Myeloma Cell Apoptosis: A Study of Nuclear Factor-B Inhibition and Gene Expression Signature

Departments of Rheumatology (S.O., M.M., N.F.), Clinical Chemistry and Human Genetics (P.C., A.C., M.-P.M., V.B.), Hematology (E.C.), Pathology (L.d.L.), and Genetic Engineering (S.T.), Center for Biomedical Integrative Genoproteomics, University of Liège, Centre Hospitalier Universitaire Sart-Tilman, Liège, Belgium

Because multiple myeloma remains associated with a poor prognosis, novel drugs targeting specific signaling pathways are needed. The efficacy of selective estrogen receptor modulators for the treatment of multiple myeloma is not well documented. In the present report, we studied the antitumor activity of raloxifene, a selective estrogen receptor modulator, on multiple myeloma cell lines. Raloxifene effects were assessed by tetrazolium salt reduction assay, cell cycle analysis, and Western blotting. Mobility shift assay, immunoprecipitation, chromatin immunoprecipitation assay, and gene expression profiling were performed to characterize the mechanisms of raloxifene-induced activity. Indeed, raloxifene, as well as tamoxifen, decreased JJN-3 and U266 myeloma cell viability and induced caspase-dependent apoptosis. Raloxifene and tamoxifen also increased the cytotoxic response to vincristine and arsenic trioxide. Moreover, raloxifene inhibited constitutive nuclear factor-B (NF-B) activity in myeloma cells by removing p65 from its binding sites through estrogen receptor interaction with p65. It is noteworthy that microarray analysis showed that raloxifene treatment decreased the expression of known NF-B-regulated genes involved in myeloma cell survival and myeloma-induced bone lesions (e.g., c-myc, mip-1, hgf, pac1,...) and induced the expression of a subset of genes regulating cellular cycle (e.g., p21, gadd34, cyclin G2,...). In conclusion, raloxifene induces myeloma cell cycle arrest and apoptosis partly through NF-B-dependent mechanisms. These findings also provide a transcriptional profile of raloxifene treatment on multiple myeloma cells, offering the framework for future studies of selective estrogen receptor modulators therapy in multiple myeloma.

Address correspondence to: Vincent Bours, Laboratory of Medical Chemistry and Human Genetics, CHU B35, Sart Tilman, 4000, Liège, Belgium. E-mail: vbours{at}ulg.ac.be

This article has been cited by other articles:

				J.-M. Renoir, C. Bouclier, A. Seguin, V. Marsaud, and B. Sola Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells J. Mol. Endocrinol., March 1, 2008; 40(3): 101 - 112. [Abstract] [Full Text] [PDF]

				S. M. Shahjahan Miah, T. L. Hughes, and K. S. Campbell KIR2DL4 Differentially Signals Downstream Functions in Human NK Cells through Distinct Structural Modules J. Immunol., March 1, 2008; 180(5): 2922 - 2932. [Abstract] [Full Text] [PDF]

				S. P. Tabruyn, C. Sabatel, N.-Q.-N. Nguyen, C. Verhaeghe, K. Castermans, L. Malvaux, A. W. Griffioen, J. A. Martial, and I. Struman The Angiostatic 16K Human Prolactin Overcomes Endothelial Cell Anergy and Promotes Leukocyte Infiltration via Nuclear Factor-{kappa}B Activation Mol. Endocrinol., June 1, 2007; 21(6): 1422 - 1429. [Abstract] [Full Text] [PDF]